Researchers at the Baylor College of Medicine have developed an experimental drug called CS18 designed to help cancer treatments overcome therapeutic resistance by targeting multiple survival mechanisms at once, according to a study published in Science Advances.
Targeting Cancer’s Survival Network Through TopBP1
Therapeutic resistance remains a primary obstacle in achieving effective and durable cancer treatments, according to Dr. Weei-Chin Lin, professor of medicine – hematology and oncology and of molecular and cellular biology at Baylor. While initial therapies often show success, patients frequently relapse because cancer cells activate compensatory pathways to survive toxic treatments. Instead of blocking a single pathway, the Baylor research team focused on topoisomerase IIß-binding protein 1 (TopBP1), which Lin described as a “biological switchboard” regulating multiple processes tied to cancer growth.
Did you know? TopBP1 contains a specific “biological switch” known as switch BRCT7/8. This region interacts with MIZ1 (a suppressor of the MYC cancer driver), mutant p53, and survival proteins PLK1 and CIP2A, making it a critical hub for intervention according to Baylor researchers.
From Chemical Screens to CS18 Development
To block the BRCT7/8 switch, investigators screened thousands of chemical compounds using computer modeling combined with laboratory experiments. This screening process identified an initial compound designated as 3B6. After modifying 3B6 and testing numerous molecular variations, the team isolated CS18 as the most effective candidate.
When CS18 binds to the BRCT7/8 switch, the cancer-promoting activities of MYC and mutant p53 decrease, DNA repair proteins lose activity, and cancer-stopping gene activity increases, as noted by Lin.
Combining CS18 with Established Therapies
Laboratory tests across multiple cancer types—including triple-negative breast cancer, ovarian cancer, lung adenocarcinoma, lung squamous cell carcinoma, and acute myeloid leukemia—revealed that CS18 maintains low toxicity toward non-cancerous cells. Furthermore, pairing CS18 with existing cancer drugs yields higher death rates in tumor cells compared to single-agent treatments.
According to findings highlighted in the study, adding CS18 to treatments such as PARP inhibitors or osimertinib successfully restored drug sensitivity in lung cancer cells that had already developed resistance to osimertinib. Animal models treated with this combination showed significant tumor growth reduction without major weight loss or outward signs of toxicity.
Frequently Asked Questions
What is CS18?
CS18 is an experimental drug developed by researchers at the Baylor College of Medicine to disrupt multiple cancer survival pathways simultaneously and overcome therapeutic resistance.

What scientific journal published the study?
The study detailing the discovery and testing of CS18 was published in the journal Science Advances.
Which existing drugs show improved effectiveness when paired with CS18?
According to the research, combining CS18 with PARP inhibitors or osimertinib enhances cancer cell death and restores drug sensitivity in resistant lung cancer cells.
Stay Updated on Oncology Breakthroughs
Explore our latest health and medical research coverage to learn more about emerging treatments and laboratory breakthroughs. Leave a comment below with your thoughts on combination cancer therapies.
Keep reading